Key Takeaways
- Learn more about the role of NT-proBNP as a predictive biomarker for HF in individuals with T2DM, and gain insights on the following topics:
- Prevalence and burden of T2DM and its association with HF
- Assessing HF risk in individuals with T2DM
- Using NT-proBNP as a biomarker for HF in T2DM
- Guidelines on the use of NT-proBNP in T2DM
About the course
The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide, accounting for around half a billion cases in 2021 alone. In addition, the risk factors for both T2DM and heart failure (HF) commonly overlap, with a magnified risk of HF in individuals with T2DM. This warrants further research into the risk assessment of HF.
Developed in collaboration with 3 regional experts across various specialties, the Heart Failure in Type 2 Diabetes Mellitus: Value of the cardiac biomarker NT-proBNP CME module focuses on the role of NT-proBNP as a predictive biomarker for HF in individuals with T2DM.
Contributors
Dr David Sim
Senior Consultant
Department of Cardiology
National Heart Centre Singapore
Past President
Heart Failure Society Singapore
Dr Bee Yong Mong
Head and Senior Consultant
Department of Endocrinology
Singapore General Hospital
Vice-President
Diabetes Singapore
Dr Phua Ling Yaw
Family Physician Partner
Parkway Shenton Family Medical Clinic Singapore
Learning outcomes
Upon completion of this module, participants will gain insights into the following topics:
- Prevalence and burden of T2DM and its association with HF
- Assessing HF risk in individuals with T2DM
- Using NT-proBNP as a biomarker for HF in T2DM
- Guidelines on the use of NT-proBNP in T2DM
Course details
Date: Available till July 2023
Location: Virtual, On-demand on the MIMS platform
(Link will be provided upon registration of interest)
Format: Powerpoint deck
Time: Around 1h for completion
1 CME / CPD point is provided upon successful completion of the module quiz. Sign up now to get access to the free course!